Navigation Links
Zimmer and ISTO Technologies Announce Phase III Clinical Study to Evaluate the Effectiveness of Engineered Juvenile Cartilage to Repair Damaged Knees

SAN FRANCISCO, Feb. 7, 2012 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal health, and ISTO Technologies, Inc., an orthobiologics company focused on developing breakthrough products to regenerate and restore function to damaged cartilage and bone, today announced a Phase III clinical study to evaluate DeNovo® ET Engineered Tissue Graft, an engineered cartilage implant intended to repair cartilage defects in the knee.  DeNovo ET Graft is being developed under a collaborative relationship between ISTO and Zimmer. 

"The DeNovo ET Graft program represents a natural extension to our early intervention and joint preservation portfolio," said Cheryl R. Blanchard, Ph.D., Senior Vice President and Chief Scientific Officer at Zimmer.  "This Phase III study will generate meaningful data on the potential of this novel biological solution for treatment of cartilage lesions earlier in the continuum of care."

The Phase III study will comprise a randomized, controlled clinical trial involving 225 patients at up to 25 centers in the United States. The program is designed to demonstrate superiority of DeNovo ET Graft over the current standard of care (microfracture) for articular cartilage defects.  

In preclinical studies, cartilage cells derived from juvenile tissue demonstrated a significantly greater capacity for regenerating cartilage compared to cells derived from adult cartilage.  Recognizing and harnessing the significant regenerative capacity differences between adult and juvenile cells is an underlying principle of ISTO's platform for cartilage repair.  In addition, through a proprietary scalable manufacturing process, ISTO has developed a platform technology for cartilage regeneration using juvenile cartilage cells.

"It is gratifying for our team to see our breakthrough cartilage repair technology advancing from research into a late stage clinical trial for what is clearly a large unmet medical need," said Mitchell Seyedin, Ph.D., President and CEO of ISTO. 

More information about the Phase III clinical study is available at

About Zimmer
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products.  Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.  Zimmer's 2011 sales were approximately $4.5 billion.  The Company is supported by the efforts of more than 8,500 employees worldwide.  For more information about Zimmer, visit

About ISTO

ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sports medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at  

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management.  Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology.  These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially.  For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE Zimmer Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zimmer Announces Acquisition of Synvasive Technology, Inc.
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2011 Results
3. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
4. Zimmer Introduces New CLS® Brevius™ Hip Stem with Kinectiv® Technology in the United States
5. Zimmer to Establish Asia-Pacific Research and Development Center
6. Zimmer Announces Acquisition of XtraFix® External Fixation System
7. Zimmer Holdings, Inc. Agrees to Sell $550 Million of Senior Notes
8. Zimmer Holdings, Inc. Announces Offering of Senior Notes
9. Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting
10. Zimmer Holdings to Present at 2011 Credit Suisse Annual Health Care Conference
11. Zimmer Holdings, Inc. Reports Third Quarter 2011 Financial Results
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY ... products, continues to provide evidence demonstrating the accuracy of ... World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease ... that both the Company,s GLUCOCARD ® 01 meter ... high accuracy requirements. The ability to accurately measure glucose ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... sauna parts and accessories. , Sauna accessories help improve the bather experience in ... personality. From basic styles for the purist looking for simplicity in design to ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, ... Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil ... for the opening of the 5th African Network for Drugs and Diagnostics Innovation, ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based drug ... their sobriety and show through pictures what a positive difference it makes. The ... with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short ...
Breaking Medicine News(10 mins):